Background. Campylobacter species is a leading cause of bacterial gastroenteritis worldwide. Quinolone resistance has emerged as an increasing problem among persons with Campylobacter infection over the past decade, but the clinical consequences are unclear.
illness and for vulnerable individuals, such the very young or the very old [2] . In both Europe and the United States, the drug of choice for treatment-once the diagnosis has been established-is a macrolide (e.g., erythromycin) [2] [3] [4] . This often poses a therapeutic dilemma, because erythromycin appears to be effective only if it is given early in the course of illness [6] . Fluoroquinolones (e.g., ciprofloxacin) are generally preferred for empirical treatment of severe infectious diarrhea before fecal specimen test results are known [2, 5] .
In the past decade, Campylobacter resistance to quinolones has emerged as an important problem [7, 8] . In one recent study from the United Kingdom, 30% of Campylobacter jejuni isolates were resistant to quinolones [9] . There is some evidence that quinoloneresistant Campylobacter infection is associated with adverse human health consequences [10] . Most studies have focused on acute illness. Three studies (2 from the United States [11, 12] and 1 from Denmark [13] ) have suggested that infection with quinolone-resistant Campylobacter strains is associated with a longer duration of illness, although these findings have been disputed [14, 15] . By contrast, the largest study to date, which was from the United Kingdom, found no difference in the duration of illness between cases due to quinolone-resistant Campylobacter strains and those due to quinolone-susceptible Campylobacter strains [16] . None of these studies undertook any patient follow-up to examine whether quinolone-resistant strains might be associated with adverse medium-term outcomes. However, a Danish registry-based cohort study found that patients with quinolone-resistant Campylobacter infection had a 6-fold increased relative risk of an adverse event (i.e., invasive illness or death) within 30 days after the date of receipt of the sample by the laboratory, although the absolute risk was very small [17] .
We performed a case-comparison study of ciprofloxacinresistant and ciprofloxacin-susceptible Campylobacter infection to compare disease severity, duration of illness, and mediumterm clinical outcomes.
METHODS

Microbiology laboratories in Wales report all
Campylobacter isolates to the Communicable Disease Surveillance Centre of the National Public Health Service. Laboratories test isolates for antimicrobial resistance using standardized disk diffusion methods, as recommended by British Society for Antimicrobial Chemotherapy guidelines, which also define minimum inhibitory concentration (MIC) equivalents [18] . Quinolone resistance is assessed using nalidixic acid test disks on the basis of the fact that even isolates with low-level resistance typically give no zone of inhibition to this. Isolates were classified according to tentative zone diameter breakpoints, as follows: ciprofloxacin resistance, zone diameter of р17 mm and MIC of у4 mg/L; ciprofloxacin susceptibility, zone diameter of у18 mm and MIC of р2 mg/L.
The case-comparison study was conducted over an 18-month period from 1 April 2003 through 30 September 2004, with 6 months of follow-up to 31 March 2005. A case patient was defined as a person who had submitted a feces specimen that yielded a ciprofloxacin-resistant Campylobacter isolate. Comparison patients were selected at random from persons infected with a ciprofloxacin-susceptible Campylobacter isolate. The study was unmatched. The following persons were excluded from the study: persons who resided outside of Wales, persons who were deemed by their general practitioner to be too incapacitated to participate (e.g., because of dementia), persons who could not be contacted by telephone, and persons who were unable to complete a telephone interview. At baseline, a research nurse interviewed all participants by telephone within 4-6 weeks after the date of onset using a structured questionnaire. Both the nurse and the patient were blinded to case status. Participants were asked about the date of onset of illness; severity and duration of symptoms; whether the patient took antipyretics, antidiarrheals, or antibiotics for the illness; whether the patient took time off work; whether the patient had visited a general practitioner, had attended an emergency department, or had been admitted to the hospital; whether the patient had preexisting medical conditions; and whether the patient had undergone foreign travel in the 7 days before onset. A parent or guardian was interviewed if the patient was a child. Participants were excluded from the analysis of symptom duration if they did not report diarrhea (defined as у3 loose stools in a 24-h period) or if they were unable to estimate its duration.
All participants were asked to keep a symptom diary as an aide-memoire for 6 months from the date of onset, and all patients were reinterviewed by telephone using a standard questionnaire 3 months and 6 months later to ask about persisting symptoms (e.g., bowel or abdominal problems, fever, and joint pains), medication use for symptomatic relief, and additional visits to the general practitioner. If a participant could not be contacted after 2 attempts, the questionnaire was mailed to them, and they were asked to complete and return it in a prepaid envelope. Participants were also asked to return the symptom diary at the end of the study. Data from interviews and symptom diaries were linked with specimen test results when all data collection was complete.
Data were analyzed using EpiInfo, version 6.04a (Centers for Disease Control and Prevention), and Stata software, version 10 (Stata Corporation). Differences between case patients and comparison patients were investigated using x 2 and Fisher's exact tests for dichotomous variables and by analysis of variance for continuous variables. Analysis of clinical outcome tested the null hypothesis that there was no difference between patients with ciprofloxacin-resistant infection and those with ciprofloxacin-susceptible infection with regard to the frequency or severity of symptoms at baseline or to the proportion who reported various symptoms during the 3-and 6-month followup interviews. Severity of symptoms was judged on the basis of the duration of diarrhea, the peak number of stools passed in a 24-h period, time off work, use of medication, medical consultation, and hospital admission. The null hypothesis was rejected if the P value was !.05.
Additional analysis involved use of a multiple linear regression model to ascertain whether patients with ciprofloxacinresistant infection had a longer mean duration of diarrhea than did patients with ciprofloxacin-susceptible infection, after controlling for covariates that were found in univariate analysis of variance to be associated ( ) with mean duration of di-P ! .3 arrhea. Nonsignificant variables were removed one by one, removing those with the largest P value first, until all remaining variables in the model were statistically significant. The study was approved by the South West Multi-Centre research ethics committee.
RESULTS
We recruited 145 case patients and 411 comparison patients, after exclusion of 56 patients; 27 were excluded because their addresses were not known, 12 resided outside of Wales, and 13 were not suitable for clinical reasons. All 556 participants conducted an interview at baseline, 430 (77.3%) completed all 3 interviews (baseline, 3-month, and 6-month), 15 (2.7%) completed the baseline and month 3 follow-up interview, 84 (15.1%) completed the baseline and final interview, and 26 (4.7%) completed only the baseline interview. In addition, 330 participants (59.3%) completed and returned the symptom diary.
Of the 556 participants, 51% were male, and the median age was 50 years (range, 0-88 years). The most common clinical symptoms were diarrhea (95%), abdominal pain (89%), weakness (83%), and fever (75%). The median ages of patients with ciprofloxacin-resistant Campylobacter infection and of those with ciprofloxacin-susceptible infection were 53 years (range, 1-86 years) and 49 years (range, 0-88 years), respectively ( ). Significantly more patients with ciprofloxacin-resis-P p .03 tant Campylobacter infection reported foreign travel, compared with patients with ciprofloxacin-susceptible Campylobacter infection (51% vs. 6%; odds ratio [OR], 16.8; 95% confidence interval [CI], 9.7-29.6;
). Acute illness due to cipro-P ! .001 floxacin-resistant and ciprofloxacin-susceptible Campylobacter infection did not differ, as assessed by frequency of diarrhea, presence of blood in stools, abdominal pains, or vomiting (table  1) . However, patients with ciprofloxacin-resistant Campylobacter infection were less likely to report fever (OR, 0.5; 95% CI, 0.3-0.7; ) or to take antipyretics (e.g., aspirin or acet-P ! .001 aminophen; OR, 0.6; 95% CI, 0.4-0.9; ) than were pa-P p .02 tients with ciprofloxacin-susceptible Campylobacter infection. The reduced likelihood of fever (adjusted OR, 0.5; 95% CI, 0.3-0.8) in patients with ciprofloxacin-resistant Campylobacter infection remained after adjustment for the effect of age, sex, and foreign travel.
Data on 513 persons (92%) were available for the analysis of symptom severity, after we excluded 27 persons who reported no diarrhea and 16 persons (7 patients with ciprofloxacinresistant and 9 patients with ciprofloxacin-susceptible Campylobacter infection) who were unable to estimate diarrhea duration (figure 1). The duration of acute illness, as assessed by mean duration of diarrhea, was 8.2 days (median, 6.0 days; range, 2-35 days) in patients with ciprofloxacin-resistant Campylobacter infection and 8.6 days (median, 7.0 days; range, 1-42 days) in patients with ciprofloxacin-susceptible Campylobacter infection (
). There were no differences between P p .57 patients with ciprofloxacin-resistant versus ciprofloxacinsusceptible Campylobacter infection with regard to the peak number of stools in 24 h (10.8 vs. 11.2 episodes;
), у7-P p .64 day duration of diarrhea (48% vs. 52% of patients;
), P p .43 mean duration of missed work or school (8.3 vs. 8.6 days;
), or hospitalization (9.0% vs. 8.5% of patients; P p .84 P 1 ). . 99 We also analyzed the effect of potential covariates on the duration of diarrhea. There was a small but significant relationship between age and duration of diarrhea, with a regression coefficient of Ϫ0.04 days/year (95% CI, Ϫ0.06 to Ϫ0.01 days/year; ). Duration of diarrhea was not associated P ! .01 with foreign travel: among 87 travelers, the mean durations of diarrhea were 8.9 and 9.2 days ( ) for patients with P p .64 ciprofloxacin-resistant Campylobacter infection and those with ciprofloxacin-susceptible Campylobacter infection, respectively; and among 426 nontravelers, the mean durations of diarrhea were 7.5 and 8.5 days, respectively ( ). The mean du-P p .21 ration of diarrhea did not differ among patients with diabetes or preexisting bowel problems or among those who took antipyretics, antidiarrheals (e.g., diphenoxylate or loperamide), or ciprofloxacin. However, 71 patients who took erythromycin had diarrhea for a mean of 10.8 days, compared with 8.1 days among 442 patients who did not take erythromycin (P p ). We explored these interactions further in a restricted .001 analysis that compared the duration of diarrhea in various subcategories of patients with ciprofloxacin-resistant versus ciprofloxacin-susceptible Campylobacter infection (figure 1). Among patients who took no antidiarrheals, the mean duration of diarrhea was 7.7 days (median, 6.0 days) among 60 patients with ciprofloxacin-resistant Campylobacter infection and 8.3 days (median, 6.0 days) among 166 patients with ciprofloxacinsusceptible Campylobacter infection ( ). Among patients P p .48 who were treated with ciprofloxacin but who did not take antidiarrheals, the mean duration of diarrhea was 6.3 days (median, 5.5 days) among 6 patients with ciprofloxacin-resistant Campylobacter infection and 6.6 days (median, 6.0 days) among 23 patients with ciprofloxacin-susceptible Campylobacter infection ( ). P p .89 Factors associated with mean duration of diarrhea in univariable analysis, including age, antidiarrheal medication, any antibiotic use, and erythromycin use, were analyzed in a multivariable model (table 2) . When we controlled for these predictor variables, there was still no difference between mean duration of diarrhea among patients with ciprofloxacin-resistant Campylobacter infection versus those with ciprofloxacinsusceptible Campylobacter infection (coefficient, Ϫ0.12; 95% CI, Ϫ1.37 to 1.13;
) . When all noncontributory var-P p .85 iables were removed from the model, only age and erythromycin use remained statistically significant. Patients who took erythromycin experienced an increase in the duration of diarrhea of 2.8 days after adjustment for age (data not shown).
In the follow-up component of the study, patients with ciprofloxacin-resistant Campylobacter infection were no more likely than patients with ciprofloxacin-susceptible Campylobacter infection to report any symptoms during the 3-month follow-up interview (OR, 1.3; 95% CI, 0.8-2.0) or during the 6-month follow-up interview (OR, 0.9; 95% CI, 0.6-1.4). No individual symptoms occurred more frequently among patients with ciprofloxacin-resistant Campylobacter infection than among patients with ciprofloxacin-susceptible Campylobacter infection at the 3-month follow-up interview, but more patients with ciprofloxacin-resistant Campylobacter infection reported bloody diarrhea at the 6-month interview, although the number of reports was very small. There was no difference between patients with ciprofloxacin-resistant versus ciprofloxacin-susceptible Campylobacter infection with regard to the frequency of general practitioner consultation at either 3 or 6 months. Finally, analysis of symptom diaries by month revealed no differences in the frequency of symptoms recorded by month (data not shown).
DISCUSSION
Several epidemiological studies have demonstrated that infection with drug-resistant non-Typhi Salmonella enterica serotypes are associated with excess mortality and morbidity [10] . It is unclear whether infection with quinolone-resistant Campylobacter species has adverse clinical consequences, and studies published to date have produced conflicting results. This is partly because it is difficult to adjust for potential confounders, such as foreign travel, use of antidiarrheal medication, and use of antimicrobials. Our case-comparison study found no evidence of more-severe or prolonged acute illness in patients with quinolone-resistant Campylobacter infection even after adjust-ment for several potential covariates. In addition, we found no evidence of any adverse medium-term effects during 6 months of follow-up. Therefore, our data are consistent with the hypothesis that the virulence of quinolone-resistant organisms does not differ from that of susceptible strains. Some previous studies have suggested that quinolone-resistant Campylobacter infection produces prolonged diarrhea [11] [12] [13] . In a study in Minnesota from 1996-1997, the median duration of diarrhea in patients treated with a fluoroquinolone was longer in those with quinolone-resistant infection than those with quinolone-susceptible infection (10 vs . 7 days; ), although analysis was based on small numbers and P p .03 did not control for foreign travel or use of antidiarrheal medication [11] . In a Danish study, the mean duration of diarrhea was also found to be longer for 86 persons with quinoloneresistant infection than for 381 patients with quinolonesusceptible infection (13 vs. 10 days;
) and was in-P p .001 dependent of foreign travel [13] . However, the UK Campylobacter Sentinel Surveillance Scheme, which analyzed data on 2097 travel-related cases of C. jejuni infection and 8746 domestically acquired cases of C. jejuni infection [15, 16] , found no difference in the duration of illness between drug-resistant and drug-susceptible infections with regard to either domestic or foreign cases. A recent Australian study also found no difference in median duration of diarrhea, hospitalization rates, or duration of hospitalization between drug-resistant and drugsusceptible infection, although these results were based on small numbers [22] . Neither the studies from the United Kingdom [15, 16] or Australia [22] controlled for treatment with antidiarrheal or antimicrobial medication. The discrepancies between these studies are probably due to a combination of factors, such as differences in study design and analysis, or variation in clinical practice, such as timing of antibiotic therapy or prescribing rates for Campylobacter infection.
Our study most closely mirrors the FoodNet study [12] in size, conception, and design, although susceptibility tests were performed using disk diffusion methods similar to those used in the Minnesota and Danish studies [11, 13] . The FoodNet study analyzed data on 740 persons with Campylobacter infection during 1998-1999, of whom 82 had quinolone-resistant infection. Among 290 persons who did not take antidiarrheal medication, the mean duration of diarrhea was longer in the 26 persons with quinolone-resistant infection than in the 264 persons with quinolone-susceptible infection (9 vs. 7 days;
) and was independent of foreign travel. However, there P p .04 was no significant difference in the mean duration of diarrhea between persons with fluoroquinolone-resistant or fluoroquinolone-susceptible infection in the small subset of 85 persons treated with a fluoroquinolone (8 vs. 6 days;
). Inter-P p .2 estingly, the FoodNet study also found that ciprofloxacin treatment was ineffective, even for susceptible infections. In our study, the duration of diarrhea actually increased among patients treated with erythromycin, even after adjustment for age and antidiarrheal use, perhaps because only patients with moresevere disease were prescribed antibiotics or because antibiotics were prescribed too late to reduce the duration of illness.
It is also possible that antibiotics are less efficacious against Campylobacter infection than has been previously supposed. There have been relatively few trials of antibiotic treatment versus placebo in patients with Campylobacter infection, although a recent meta-analysis of 11 randomized, controlled trials found that antibiotic treatment shortened the duration of symptoms by 1.3 days [6] . However, only 6 trials tested erythromycin use, and only 2 of these included adults, neither of which showed a significant positive effect favoring erythromycin. This highlights the need for further randomized, controlled trials, not only to establish beyond doubt the efficacy of erythromycin and fluoroquinolones for treating Campylobacter infection, but also to identify the patient groups most likely to benefit from treatment.
Our study has several limitations. First, selection of study participants was based on routine laboratory reports. Because Campylobacter isolates are not routinely speciated in Wales, our data do not distinguish between infection with C. jejuni or Campylobacter coli, although most infections (∼90%) are probably due to C. jejuni. Participating laboratories used disk diffusion methods to determine quinolone resistance. This approach has been questioned, because no standardized methods or interpretive criteria have been established [19, 20] . However, although breakpoints are tentative, it is generally easy to distinguish ciprofloxacin-resistant and ciprofloxacin-susceptible Campylobacter isolates phenotypically on the basis of zone diameters on nalidixic acid disks, because most ciprofloxacinresistant isolates exhibit high-level resistance to nalidixic acid. Second, as with any retrospective study, there is potential for recall bias among respondents, although this is much less likely in a case-comparison study in which both groups have experienced similar illness [21] . Follow-up data were collected very assiduously from both groups using a symptom diary, to ensure accurate recall, and a structured questionnaire, to ensure objective recording. Furthermore, both patients and research nurses were blinded to patient status to reduce the possibility of observer bias. Third, the study takes no account of the timing of antibiotic treatment. Early treatment is vital to shorten duration of illness. Because we have no data on the timing of treatment, we cannot exclude the possibility that similar duration of diarrhea in case patients and comparison patients is a consequence of delayed treatment rather than ciprofloxacin failure in patients with ciprofloxacin-resistant infection. Another problem is that ciprofloxacin can select for ciprofloxacinresistant strains, even when the infecting strain is susceptible to ciprofloxacin, giving rise to misclassification bias. Routine clinical practice in the United Kingdom is to obtain fecal specimens before commencement of antibiotic treatment, and it is therefore unlikely that this will have occurred in the patients in our study. Finally, our sample of patients treated with ciprofloxacin but no antidiarrheal was small.
In conclusion, we found no evidence of more-severe or prolonged illness in participants with quinolone-resistant Campylobacter infection and no evidence of any adverse mediumterm consequences. This challenges the view that there is a substantial health burden associated with quinolone-resistant Campylobacter infection [23, 24] . Claims that quinolone resistance leads to 1400,000 excess days of diarrhea per year in the United States are based on very tenuous evidence [23] . Our study, in common with the results of several other studies [15, 16, 22] , suggests that the clinical and public health significance of quinolone resistance in Campylobacter infection may have been overestimated.
